Ranitidine patent 1979?

Who owned the 1979 ranitidine patent?
The U.S. Patent No. 4,285,280, issued in 1979, was granted to G.D. Searle & Company. The patent covered the chemical structure of ranitidine and its use as an H₂‑receptor antagonist for treating gastric acid disorders. The patent later transferred with Searle’s pharmaceutical assets to Monsanto, then to Pfizer in 2000, and ultimately to GlaxoSmithKline when Pfizer sold its consumer‑health unit in 2002.  [1]

What did the patent actually claim?
The claims described ranitidine’s structure—specifically, the 1‑methyl‑4‑[2‑(propyl‑hydrazino)‑2‑pyrimidinyl]‑piperazine—and its therapeutic use in reducing stomach acid production. It also included methods for synthesizing the compound and its pharmaceutical compositions.  [1]

When did the patent expire, and how did that affect the market?
Filed in 1977, the 1979 patent expired in 1997 after a 20‑year term. Once expired, other manufacturers were free to produce generic ranitidine, which entered the market in the early 2000s and increased competition for Zantac.  [1]

Are there any remaining active patents for ranitidine?
No, the original 1979 patent has long expired. Later patents covering specific formulations or manufacturing methods have also lapsed. Generic manufacturers currently produce ranitidine, although the drug has largely fallen out of use after its recall in 2020 over NDMA contamination concerns.  [1]

How did the 1979 patent shape ranitidine’s commercial success?
With exclusive rights during its life, Searle was the sole producer of ranitidine, allowing it to establish market dominance as the first over‑the‑counter H₂ blocker. The patent’s protection enabled the company to invest heavily in marketing, leading to widespread adoption and high sales before generics entered.  [1]

Why was ranitidine recalled in 2020 despite the patent’s expiration?
The recall was due to the detection of NDMA, a probable carcinogen, in many ranitidine products. It was a safety issue, not a patent issue.  [1]

---

Sources
[1] DrugPatentWatch – Ranitidine (Zantac) Patent 1979. https://www.drugpatentwatch.com/ranitidine-patent-1979